Advanced Filters
noise

Beijing, China Clinical Trials

A listing of Beijing, China clinical trials actively recruiting patients volunteers.

Found 2,316 clinical trials
L Liang Wang, M.D.

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, we supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in …

14 - 85 years of age All Phase 2

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

8 - 45 years of age Male Phase N/A

Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline

This study investigates the neural mechanisms of cognitive function decline, cognitive assessment methods for subjects with mild cognitive dysfunction (Mild cognitive impairment, MCI, or cognitive decline milder than MCI), and the approaches used to improve and restore cognitive function.

18 years of age All Phase N/A
J Jun Guo, Director

Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors

This is an open-labeled, single-center phase I study in patients with incurable advanced solid tumors, who failed with all previous standard therapy. The aim is to observe and evaluate the safety, tolerability, and immunogenicity of LK101 injection.

18 - 75 years of age All Phase 1
J Jie Wang, Professor

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

18 years of age All Phase 1/2

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy combined with Lenvatinib and PD-1 inhibitors compared to Lenvatinib plus PD-1 inhibitors for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).

18 - 80 years of age All Phase 2
S Sun Yao, M.D.,Ph.D.

Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia

The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of acute myeloid leukemia (AML) patients by eradicating minimal residual disease, while maintaining its safety profile in this phase I trial.

18 - 70 years of age All Phase N/A
W Weishi Li

A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

The primary objective of the study is to assess the overall efficacy of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion.

18 - 80 years of age All Phase 3
H Hongli Jing

99mTc-ABH2 SPECT/CT in Breast Cancer

This prospective study will investigate the potential usefulness of 99mTc-ABH2 SPECT/CT in the diagnostic performance and evaluation efficacy of breast cancer.

18 - 80 years of age Female Phase N/A

A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX

Aprospective, multicentre, single-arm clinical trial in which approximately 36 subjects would be enrolled using the Bridge 4.5 mm and 5.0 mm stent in accordance with the inclusion and exclusion criteria in this protocol. The success rate of immediate post-procedure stent target lesion treatment was recorded for all subjects, and the …

18 - 80 years of age All Phase N/A

Simplify language using AI